Ibex Prostate Detect is designed to help pathologists catch small and rare cancers in whole-slide images from tissue biopsies that they might've missed.

The biopharma company, which is developing cell therapies for cancers and autoimmune diseases, said it will use the proceeds for working capital.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

NEW YORK – The US Food and Drug Administration has cleared Aro Biotherapeutics' investigational new drug application for a short-interfering RNA (siRNA) drug it's developing for late-onset Pompe ...

NEW YORK – Viracta Therapeutics on Wednesday shuttered and laid off all employees. The financially beleaguered San Diego-based company last fall laid off 42 percent of its employees and reduced the ...

NEW YORK – AstraZeneca is hoping for a positive readout this year from the SERENA-6 Phase III trial of its investigational complete estrogen receptor antagonist camizestrant, which could set the drug ...

The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...